A cell-penetrating peptide ferry carried the antidepressant sulpiride across the blood-brain barrier more effectively, improving depression scores in mice while reducing the side effect of elevated prolactin.
Better brain delivery + fewer side effectsThe CPP-sulpiride conjugate improved antidepressant efficacy in mice while reducing serum prolactin — solving two problems at once by enhancing blood-brain barrier crossing
What the researchers found
Linking the antidepressant drug sulpiride to a cell-penetrating peptide (VPALR, derived from the DNA repair protein Ku70) created a conjugate (VPALR-SUL) that crossed the blood-brain barrier more effectively than sulpiride alone. In depressed mice, VPALR-SUL significantly improved two key depression measures — increased struggle time and total distance — compared to sulpiride alone.
Critically, the conjugate also reduced serum prolactin levels — addressing a major side effect of sulpiride. The drug normally can't reach the brain's pituitary gland well enough to suppress prolactin release, causing hyperprolactinemia (elevated prolactin with side effects like sexual dysfunction and breast changes). Pharmacokinetic data showed VPALR-SUL had a longer half-life and better bioavailability than sulpiride alone.
Why it matters
The blood-brain barrier blocks many promising psychiatric drugs from reaching their targets in the brain. Cell-penetrating peptides offer a biological solution — acting as molecular delivery vehicles that carry drugs across this barrier. This study demonstrates the concept with a real clinical problem: sulpiride works for depression but causes troublesome prolactin side effects precisely because it can't cross the BBB efficiently. By attaching a CPP, researchers simultaneously improved efficacy and reduced a key side effect — a double win that could apply to many other brain-targeted drugs.
The numbers in context
VPALR peptide (from Ku70 protein) · Increased struggle time + total distance in depressed mice · Reduced serum prolactin vs sulpiride alone · Prolonged half-life · Increased bioavailability
How the study worked
Researchers covalently linked sulpiride to the cell-penetrating peptide VPALR. The conjugate was tested in a mouse model of depression using intraperitoneal injection. Depression-related behaviors (struggle time, total distance) were measured. Serum prolactin levels were compared between VPALR-SUL and sulpiride-only groups. Pharmacokinetic studies assessed half-life and bioavailability of the conjugate.
Who was studied
Mouse model of depression (animal study)
What this study cannot tell us
This is an animal study in mice — behavioral measures of depression in mice don't perfectly translate to human depression. The specific mechanism by which VPALR-SUL crosses the BBB better was not fully characterized. Long-term safety of the peptide-drug conjugate is unknown. The VPALR peptide itself may have immunogenic potential in humans. Manufacturing complexity of peptide-drug conjugates could limit clinical development.
How to read the evidence
This is early-stage animal research using a mouse model of depression. The behavioral and pharmacokinetic data are encouraging, but mouse depression models have significant limitations. No human data exists for this conjugate.
When this study was published
Published in 2024. This is current research in the active field of peptide-mediated drug delivery to the brain.
The bigger picture
The blood-brain barrier remains one of the biggest challenges in developing drugs for brain diseases including depression, Alzheimer's, Parkinson's, and brain cancers. Cell-penetrating peptides represent one of the most promising approaches to overcoming this barrier. This study adds to growing evidence that CPP-drug conjugates can simultaneously improve brain delivery and reduce peripheral side effects — a strategy that could be applied to dozens of existing drugs that work in principle but can't reach the brain effectively.
Questions still open
- Would VPALR-SUL show the same benefits in humans, where the blood-brain barrier properties differ from mice?
- Could the VPALR peptide be used to ferry other psychiatric drugs across the BBB with similar improvements?
- What are the long-term safety implications of repeated administration of a cell-penetrating peptide conjugate?
Common questions
What is a cell-penetrating peptide?
Why does sulpiride cause elevated prolactin?
Read the original research
Conjugation of sulpiride with a cell penetrating peptide to augment the antidepressant efficacy and reduce serum prolactin levels.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 174, 116610
Citation
Liang, Yuan; Yang, Yu; Huang, Ruiyan; Ning, Jiangyue; Bao, Xingyan; Yan, Zelong; Chen, Haotian; Ding, Li; Shu, Chang. (2024). Conjugation of sulpiride with a cell penetrating peptide to augment the antidepressant efficacy and reduce serum prolactin levels.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 174, 116610. https://doi.org/10.1016/j.biopha.2024.116610